Visallergol, eye drops 0.2% 2.5ml

Pharmacokinetics

Absorption
Olopatadine undergoes systemic absorption similar to other topical medications. However, plasma concentrations of olopatadine after its topical application in ophthalmology are low and range from below quantification (< 0.5 ng/mL) to 1.3 ng/mL. Reported plasma concentrations are 50-200 times lower than those of oral administration of therapeutic doses of olopatadine. According to the results of comparative studies of pharmacokinetics of 10 mg oral dosage form of olopatadine in young (mean age – 21 years) and old patients (mean age – 74 years) no significant differences in concentrations of olopatadine in plasma, binding to plasma proteins and parameters of drug excretion in unchanged form and as metabolites were noted.

Pharmacodynamics

Olopatadine is a powerful selective anti-allergic/antihistamine drug whose pharmacological effects are developed through several different mechanisms of action. It is an antagonist of histamine (the main mediator of allergic reactions in humans) and prevents histamine-induced release of inflammatory cytokines in conjunctival epithelial cells. In vitro studies suggest inhibition of release of anti-inflammatory mediators by conjunctival mast cells.
In patients with patent nasolacrimal ducts local application of olopatadine in the form of instillations into the conjunctival sac reduced the severity of nasal symptoms often accompanying seasonal allergic conjunctivitis. Olopatadine has no clinically significant effect on pupil diameter.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Synopsis

Contraindications

Hypersensitivity to the ingredients of the drug.

Children under 2 years of age.

Pregnancy and breastfeeding.

Side effects

System-organ class

Frequency of occurrence

Adverse events

Infectious disorders

Infrequent

Rhinitis

Immune system disorders

/p>

Frequency unknown

Hypersensitivity, facial swelling

Nervous system disorders

Often

/p>

Infrequent

Frequency unknown

Headache, dysgeusia

Dizziness, hypoesthesia

Sleepiness

/p>

Visual disturbances

Often

Infrequent

p>

Frequency unknown

Pain in the eye, eye irritation, dry eye syndrome, unusual sensation in the eye.

Corneal erosion, corneal epithelial defect, pitting keratitis, keratitis, accumulation of dye pigment in the area of corneal defect in diagnostic tests, ocular discharge, photophobia, blurred vision, decrease in visual acuity, blepharospasm, discomfort in the eye, itching in the eye, conjunctival folliculosis, conjunctival disorders, feeling of a foreign body in the eye, lacrimation, erythema of the eyelids, eyelid edema, eyelid disorders,

conjunctival injection.

Corneal edema, conjunctival edema, conjunctivitis, mydriasis, visual impairment, crusts on the edges of the eyelids.

Respiratory system, thoracic and mediastinal disorders

Often

Frequency unknown

Nasal dryness

Dyspnea, sinusitis

Gastrointestinal tract disorders

Frequency unknown

Nausea, vomiting

/p>

Skin and subcutaneous fatty tissue disorders

Infrequent

Frequency unknown

Contact dermatitis, burning sensation of skin, dry skin.

Dermatitis, erythema.

General disorders

Often

Frequency unknown

Associative fatigue

Asthenia, malaise

/p>
In very rare cases, corneal calcification has developed when phosphate-containing drops have been used by patients with concomitant significant corneal damage.

Overdose

Similarities